Histamine receptor subtypes: A century of rational drug design

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 2, 2012, Pages 461-488

  Walter, Miriam ^a   Stark, Holger ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Drug design; Drug development; Histamine; Medicinal chemistry; Receptor; Review

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; BAMIPINE; DIMETINDENE; DIPHENHYDRAMINE; DOXYLAMINE; GSK 239512; GSK 334429; HISTAMINE AGONIST; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR AGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR AGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; JNJ 17216498; MEPYRAMINE; MK 0249; OLANZAPINE; PF 3654746; PITOLISANT; SCH 497079; UNCLASSIFIED DRUG; UNINDEXED DRUG; UR 63325; ANTIHISTAMINIC AGENT; G PROTEIN COUPLED RECEPTOR;

ALLERGIC RHINITIS; ALLERGY; ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CHROMOSOMAL LOCALIZATION; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DNA FLANKING REGION; DNA SEQUENCE; DRUG DESIGN; DRUG EFFECT; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; EPILEPSY; FOOD INTAKE; HUMAN; IMMUNOPATHOLOGY; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; LIGAND BINDING; MOLECULAR CLONING; MOTION SICKNESS; NARCOLEPSY; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PHARMACOPHORE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PROTEIN LOCALIZATION; PRURITUS; RECEPTOR BINDING; SCHIZOPHRENIA; SIDE EFFECT; SKIN ALLERGY; SLEEP DISORDER; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; URTICARIA; WAKEFULNESS; WEIGHT GAIN; CHEMISTRY; CLASSIFICATION; METABOLISM; REVIEW;

DRUG DESIGN; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE;

EID: 84857974978     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (251)

1. A. Windaus, W. Vogt: Synthese des Imidazolyläthylamins. Ber Dtsch Chem Ges 40, 3691-3695 (1907)
2. H. H. Dale, P. P. Laidlaw: The physiological action of beta-imidazolylethylamine. J Physiol 41, 318-344 (1910)
3. H. H. Dale, P. P. Laidlaw: Histamine shock. J Physiol 52, 355-390 (1919)
4. M. E. Parsons, C. R. Ganellin: Histamine and its receptors. Br J Pharmacol 147 Suppl 1, S127-S135 (2006) (Pubitemid 43077270)
5. L. Maintz, N. Novak: Histamine and histamine intolerance. Am J Clin Nutr 85, 1185-1193 (2007)
6. T. B. Paiva, M. Tominaga, A. C. Paiva: Ionization of histamine, N-acetylhistamine, and their iodinated derivatives. J Med Chem 13, 689-692 (1970)
7. J. W. Black, C. R. Ganellin: Naming of substituted histamines. Cell Mol Life Sci 30, 111-113 (1974)
8. S. J. Hill, C. R. Ganellin, H. Timmerman, J.-C. Schwartz, N. P. Shankley, J. M. Young, W. Schunack, R. Levi, H. L. Haas: International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49, 253-278 (1997) (Pubitemid 27414915)
9. 4 receptor agonist. J Pharmacol Exp Ther 314, 1310-1321 (2005) (Pubitemid 41205997)
10. 4 receptors as novel drug targets. Expert Opin Investig Drugs 18, 1519-1531 (2009)
11. 3) of histamine receptor. Nature 302, 832-837 (1983) (Pubitemid 13125123)
12. T. Oda, N. Morikawa, Y. Saito, Y. Masuho, S. Matsumoto: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275, 36781-36786 (2000) (Pubitemid 32002087)
13. 3 receptor antagonists go to clinics. Biol Pharm Bull 31, 2163-2181 (2008)
14. 4 receptor in immune and inflammatory disorders. Br J Pharmacol 157, 24-33 (2009)
15. 4R antagonist for the treatment of allergic respiratory diseases. EAACI, (2010).
16. 3 receptor. Trends Pharmacol Sci 28, 350-357 (2007) (Pubitemid 47016682)
17. 1 receptor antagonists. Eur J Pharmacol 387, R5-7 (2000) (Pubitemid 30035384)
18. 2 receptor fused to long and short splice variants of Gs alpha. J Pharmacol Exp Ther 299, 1013-1020 (2001) (Pubitemid 33104973)
19. 4 receptor. Biochemistry 48, 1424-1438 (2009)
20. T. Costa, S. Cotecchia: Historical review: negative efficacy and the constitutive activity of G protein-coupled receptors. Trends Pharmacol Sci 26, 618-624 (2005) (Pubitemid 41636306)
21. T. Kenakin: The physiological significance of constitutive receptor activity. Trends Pharmacol Sci 26, 603-605 (2005) (Pubitemid 41636302)
22. 4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther 299, 121-130 (2001) (Pubitemid 32905126)
23. 1 receptor. Proc Natl Acad Sci U S A 88, 11515-11519 (1991) (Pubitemid 21916072)
24. 1 receptor gene. Biochem Biophys Res Commun 201, 894-901 (1994) (Pubitemid 24206956)
25. 1-receptor gene. Hum Genet 94, 186-188 (1994) (Pubitemid 24232053)
26. R. A. Bakker, H. Timmermann, R. Leurs: Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 17, 27-64 (2002)
27. R. Leurs, M. K. Church, M. Taglialatela: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp All 32, 489-498 (2002) (Pubitemid 34429565)
28. J.-C. Schwartz, J. M. Arrang, M. Garbarg, H. Pollard, M. Ruat: Histaminergic transmission in the mammalian brain. Physiol Rev 71, 1-51 (1991)
29. H. Haas, P. Panula: The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 121-130 (2003) (Pubitemid 37271382)
30. 1-receptor agonists. Mini Rev Med Chem 4, 935-940 (2004) (Pubitemid 39406253)
31. N. Barak: Betahistine: what's new on the agenda? Expert Opin Investig Drugs 17, 795-814 (2008)
32. D. Bovet, A. M. Staub: Action protectrice des éthers phénoliques an cours de l'intoxication histaminique. C R Soc Biol 124, 547-549 (1937)
33. 1 antihistamines. Clin Allergy Immunol 17, 141-178 (2002)
34. G. P. Reynolds, S. L. Kirk: Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 125, 169-179 (2010)
35. M. Cvetkovic, B. Leake, M. F. Fromm, G. R. Wilkinson, R. B. Kim: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dis 27, 866-871 (1999) (Pubitemid 29347585)
36. 1-antihistamines. Clin Allergy Immunol 17, 389-419 (2002)
37. R. Leurs, M. J. Smits, H. Timmerman: Molecular pharmacological acpects of histamine receptors. Pharmacol Ther 66, 413-463 (1995)
38. 1 antihistamines). Pharm Unserer Zeit 33, 92-98 (2004) (Pubitemid 41754794)
39. 1 receptor. J Biol Chem 274, 29994-30000 (1999)
40. A. S. Ash, H. O. Schild: Receptors mediating some actions of histamine. Br J Pharmacol Chemother 27, 427-439 (1966)
41. 2 receptors. Nature 236, 385-390 (1972)
42. 2 receptor. Proc Natl Acad Sci 88, 429-433 (1991) (Pubitemid 21915478)
43. 2 receptor: gene cloning, tissue expression and chromosomal localization of its human counterpart. Biochem Biophys Res Commun 211, 570-577 (1995)
44. 4 Receptor - New Compounds for Translational Steps (2009).
45. The histamine receptors. Eds: J.-C. Schwartz, H. Haas, Wiley-Liss Inc., New York (1992)
46. 2-receptors. Clin Exp Hypertens 1, 251-265 (1978) (Pubitemid 9029273)
47. 2 receptor ligands. Mini Rev Med Chem 4, 941-954 (2004) (Pubitemid 39406254)
48. 2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4-and 5-(2-aminoethyl) thiazoles. J Med Chem 35, 3239-3246 (1992)
49. 2-receptor agonist. Part 2. Structureactivity considerations. 1977. Agents Actions 43, 139-143 (1994)
50. 2-receptor antagonist. Gastroenterology 74, 339-347 (1978) (Pubitemid 8276578)
51. 2-antagonists - past, present and future. J Clin Gastroenterol Suppl. 1, 71-79 (1983) (Pubitemid 14214243)
52. 2-receptor antagonist. Br J Pharmacol 93, 69-78 (1988)
53. 2 receptors. Proc Natl Acad Sci U S A 93, 6802-6807 (1996) (Pubitemid 26230391)
54. G. A. Patani, E. J. LaVoie: Bioisosterism: a rational approach in drug design. Chem Rev 96, 3147-3176 (1996) (Pubitemid 126641132)
55. L. M. Lima, E. J. Barreiro: Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 12, 23-49 (2005) (Pubitemid 40089827)
56. 2 Receptor Antagonists). Pharm Unserer Zeit 36, 24-32 (2007) (Pubitemid 46332666)
57. 3 heteroreceptors. Fundam Clin Pharmacol 8, 128-137 (1994) (Pubitemid 24103046)
58. R. E. Brown, D. R. Stevens, H. L. Haas: The physiology of brain histamine. Prog Neurobiol 63, 637-672 (2001) (Pubitemid 32119421)
59. 3 antagonists for treatment of cognitive deficits in CNS diseases. Curr Top Med Chem 10, 153-169 (2010)
60. 3 receptors: an overview. Ital J Gastroenterol 23, 378-385 (1991)
61. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25, 618-625 (2004) (Pubitemid 39458167)
62. 3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154, 1166-1181 (2008) (Pubitemid 351992052)
63. 3 receptor. Mol Pharmacol 55, 1101-1107 (1999) (Pubitemid 29252378)
64. 3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 293, 771-778 (2000) (Pubitemid 30417841)
65. 3 receptor heterogeneity. Life Sci 73, 3043-3072 (2003) (Pubitemid 37205140)
66. 3 receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol 131, 1247-1250 (2000)
67. 3 receptor agents across species is attributable to transmembrane 3 sequence differences. Inflamm Res 56 Suppl 1, S45-46 (2007) (Pubitemid 47345694)
68. 3 receptors. Bioorg Med Chem Lett 11, 951-954 (2001) (Pubitemid 32226222)
69. 3 receptor gene. Neuroreport 12, 321-324 (2001) (Pubitemid 32114373)
70. 3 receptor. Biochem Pharmacol 73, 1195-1204 (2007) (Pubitemid 46413181)
71. 3 receptor. Biochem J 355, 279-288 (2001) (Pubitemid 32397785)
72. 3 receptor. Neuropharmacology 42, 929-940 (2002) (Pubitemid 34632680)
73. 3 receptors regulates histamine neurons in brain. Nature 408, 860-864 (2000) (Pubitemid 32016096)
74. 3 receptors. Br J Pharmacol 135, 383-392 (2002) (Pubitemid 34151170)
75. 3 receptor expressed in CHO cells. BMC Pharmacol 8, 9 (2008)
76. 3 receptors in vitro and in vivo. Proc Natl Acad Sci U S A 100, 11086-11091 (2003) (Pubitemid 37140156)
77. 3 receptor agonist-stimulated [35S]GTP gamma (S) binding to pertussis toxin. Eur J Pharmacol 296, 223-225 (1996)
78. 3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59, 1-8 (2001) (Pubitemid 32043078)
79. 3 receptor. J Neurochem 103, 248-258 (2007) (Pubitemid 47404216)
80. 3 receptor induces phosphorylation of the Akt/GSK-3 beta pathway in cultured cortical neurons and protects against neurotoxic insults. J Neurochem 110, 1469-1478 (2009)
81. A. A. Farooqui, L. A. Horrocks: Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 12, 245-260 (2006) (Pubitemid 43725834)
82. + exchange: a novel protective mechanism in myocardial ischemia. Proc Natl Acad Sci U S A 98, 2855-2859 (2001) (Pubitemid 32209573)
83. 3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc Natl Acad Sci U S A 99, 501-506 (2002) (Pubitemid 34060390)
84. 3 receptor drugs. Nat Rev Drug Discov 4, 107-120 (2005) (Pubitemid 40277492)
85. 3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 16, 967-985 (2007) (Pubitemid 47074155)
86. 3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 14, 509-515 (2009)
87. M. M. Raga, J. Sallares, M. Guerrero, A. Guglietta: Monohydrochloride Salt of 1-(3-(3-(4-chlorophenyl) propoxy) propyl) piperidine. WO2006084833 (2006)
88. B. Blaya, F. Nicolau-Galmés, S. M. Jangi, I. Ortega- Martínez, E. Alonso-Tejerina, J. Burgos-Bretones, G. Pérez-Yarza, A. Asumendi, M. D. Boyano: Histamine and Histamine Receptor Antagonists in Cancer Biology. Inflam Allerg Drug Targets 9, 146-157 (2010)
89. 3 receptor agonist. J Pharmacol Exp Ther 263, 304-310 (1992)
90. 3 receptor agonist, 4-(1H-imidazol-4-ylmethyl) piperidine. J Med Chem 37, 332-333 (1994) (Pubitemid 24079940)
91. 3 receptor agonist. J Med Chem 47, 2414-2417 (2004) (Pubitemid 38580078)
92. 3 receptor agonist. J Med Chem 48, 2100-2107 (2005) (Pubitemid 40396337)
93. 3-receptor agonist. Curr Med Chem 8, 1329-1340 (2001) (Pubitemid 32791799)
94. 3-receptor agonist (R)-alphamethylhistamine. Bioorg Med Chem 9, 191-198 (2001) (Pubitemid 32007977)
95. 3 receptor agonist prodrug. J Pharmacol Exp Ther 295, 219-225 (2000)
96. 3 receptor with high in vitro and in vivo activity. J Med Chem 42, 4269-4274 (1999) (Pubitemid 29483045)
97. 3-receptor antagonists and partial agonists with a nonaminergic structure. Br J Pharmacol 132, 1665-1672 (2001) (Pubitemid 32397958)
98. J. J. Stephanos: Drug-protein interactions: two-site binding of heterocyclic ligands to a monomeric hemoglobin. J Inorg Biochem 62, 155-169 (1996) (Pubitemid 126334783)
99. 3 receptor antagonists and antipsychotic drugs. Brain Res 1045, 142-149 (2005) (Pubitemid 40725230)
100. H. S. Chadha, M. A. Abraham, R. C. Mitchell: Physicochemical analysis of the factors governing distribution of solutes between blood and brain. Bioorg Med Chem Lett 4, 2511-2516 (1994) (Pubitemid 24342936)
101. 3 receptor antagonists. Mini Rev Med Chem 4, 965-977 (2004) (Pubitemid 39406256)
102. 3 receptors. J Pharmacol Exp Ther 271, 452-459 (1994)
103. 3 receptor heterogeneity? Naunyn Schmiedebergs Arch Pharmacol 353, 482-488 (1996)
104. S. Harusawa, M. Kawamura, L. Araki, R. Taniguchi, H. Yoneyama, Y. Sakamoto, N. Kaneko, Y. Nakao, K. Hatano, T. Fujita, R. Yamamoto, T. Kurihara, A. Yamatodani: Synthesis of novel 4 (5) - (5-aminotetrahydropyran-2-yl) imidazole derivatives and their in vivo release of neuronal histamine measured by brain microdialysis. Chem Pharm Bull (Tokyo) 55, 1245-1253 (2007) (Pubitemid 47344982)
105. 3 antagonists. Expert Opin Ther Pat 17, 675-687 (2007) (Pubitemid 47045530)
106. 3 receptor antagonists reach out for the clinic. Drug Discov Today 10, 1613-1627 (2005) (Pubitemid 41817610)
107. 3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther 320, 365-375 (2007) (Pubitemid 46025751)
108. R. Xynas, R. J. Capon: Two new bromotyrosinederived metabolites from an Australian marine sponge, Aplysina sp. Aust J Chem 42, 1427-1433 (1989)
109. 3 receptor antagonists. J Med Chem 51, 5423-5430 (2008)
110. 3 antagonists. Bioorg Med Chem 12, 2603-2616 (2004) (Pubitemid 38542785)
111. 3 receptor antagonists. Bioorg Med Chem Lett 16, 897-900 (2006) (Pubitemid 43059847)
112. 3 receptor antagonists: 4-(aminoalkoxy) benzylamines. J Med Chem 46, 3938-3944 (2003) (Pubitemid 37034142)
113. 3 receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des 21, 437-453 (2007) (Pubitemid 47423277)
114. 3 receptor antagonist complexes and their pharmacophore. J Mol Graph Model 24, 456-464 (2006)
115. 3 antagonist. Br J Pharmacol 143, 649-661 (2004) (Pubitemid 39524283)
116. 3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 73, 1084-1096 (2007) (Pubitemid 46413171)
117. 3 receptor antagonists with high CNS penetration. Bioorg Med Chem Lett 17, 1443-1446 (2007)
118. R. Faghih, W. Dwight, A. Vasudevan, J. Dinges, S. E. Conner, T. A. Esbenshade, Y. L. Bennani, A. A. Hancock: Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. Bioorg Med Chem Lett 12, 3077-3079 (2002)
119. 3 receptor antagonist. Eur J Pharmacol 487, 183-197 (2004) (Pubitemid 38368996)
120. 3 antagonists/inverse agonists. Biochem Pharmacol 71, 1103-1113 (2006) (Pubitemid 43361919)
121. 3 receptor antagonists. Eur J Pharm Sci 13, 249-259 (2001) (Pubitemid 32522577)
122. 3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett 18, 355-359 (2008)
123. 3 histamine receptor. Chem Med Chem 5, 206-212 (2010)
124. 3 receptor antagonists. Bioorg Med Chem Lett 19, 6176-6180 (2009)
125. 3 receptor antagonists. J Med Chem 47, 2833-2838 (2004) (Pubitemid 38656736)
126. 3 receptor models. Br J Pharmacol 112, 1043-1048 (1994)
127. 3 receptor antagonists. Eur J Med Chem 44, 4413-4425 (2009)
128. 3 receptor. WO 2006097691 (2006)
129. L. A. Black, M. D. Cowart, G. A. Gfesser, B. D. Wakefield, R. J. Altenbach, H. Liu, C. Zhao, G. C. Hsieh: Benzothiazole and benzoxazole derivatives and methods of use. WO 2009085945A1 (2009)
130. 3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain 138, 61-69 (2008)
131. 3 receptors by PET. J Nucl Med 50, 2064-2072 (2009)
132. 3 receptor atagonists. Bioorg Med Chem Lett 20, 1581-1584 (2010)
133. 3 receptor ligands. Chem Med Chem 2, 708-716 (2007)
134. 3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett 19, 538-542 (2009)
135. 3 receptor antagonists. Bioorg Med Chem Lett 19, 2172-2175 (2009)
136. D. G. Raible, T. Lenahan, Y. Fayvilevich, R. Kosinski, E. S. Schulman: Pharmacologic characterization of a novel histamine receptor on human eosinophils. Am J Respir Crit Care Med 149, 1506-1511 (1994) (Pubitemid 24175967)
137. 3 receptors. FEBS Lett 404, 289-293 (1997) (Pubitemid 27113470)
138. 4R. Biochem Biophys Res Commun 279, 615-620 (2000) (Pubitemid 32016763)
139. 4)
140. K. L. Morse, J. Behan, T. M. Laz, R. E. West, Jr., S. A. Greenfeder, J. C. Anthes, S. Umland, Y. Wan, R. W. Hipkin, W. Gonsiorek, N. Shin, E. L. Gustafson, X. Qiao, S. Wang, J. A. Hedrick, J. Greene, M. Bayne, F. J. Monsma, Jr.: Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296, 1058-1066 (2001) (Pubitemid 32187382)
141. T. Nguyen, D. A. Shapiro, S. R. George, V. Setola, D. K. Lee, R. Cheng, L. Rauser, S. P. Lee, K. R. Lynch, B. L. Roth, B. F. O'Dowd: Discovery of a novel member of the histamine receptor family. Mol Pharmacol 59, 427-433 (2001) (Pubitemid 32179919)
142. Y. Zhu, D. Michalovich, H. Wu, K. B. Tan, G. M. Dytko, I. J. Mannan, R. Boyce, J. Alston, L. A. Tierney, X. Li, N. C. Herrity, L. Vawter, H. M. Sarau, R. S. Ames, C. M. Davenport, J. P. Hieble, S. Wilson, D. J. Bergsma, L. R. Fitzgerald: Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 59, 434-441 (2001) (Pubitemid 32179920)
143. 4 receptor gene. Biochem Biophys Res Comm 284, 301-309 (2001) (Pubitemid 32917975)
144. 4 receptor. Br J Pharmacol 157, 14-23 (2009)
145. 4 receptor. Biochem J 414, 121-131 (2008)
146. 4 receptor. Biochim Biophys Acta 1575, 135-138 (2002) (Pubitemid 34521787)
147. 4 receptor. J Pharmacol Sci 98, 319-322 (2005) (Pubitemid 41296414)
148. 4 receptor. Eur J Pharmacol 592, 26-32 (2008)
149. 4 receptors are expressed on distinct endocrine cell types in the rat fundic mucosa. Inflamm Res 57 Suppl 1, S57-58 (2008)
150. 4 receptor expression in human synovial cells obtained from patients suffering from rheumatoid arthritis. Biol Pharm Bull 28, 2016-2018 (2005) (Pubitemid 41437104)
151. 4 receptor. J Immunol 173, 2078-2083 (2004) (Pubitemid 38971645)
152. 4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 157, 55-63 (2009)
153. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305, 1212-1221 (2003) (Pubitemid 36618001)
154. 4 receptor. Br J Pharmacol 140, 1117-1127 (2003) (Pubitemid 37475978)
155. 4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 142, 161-171 (2004) (Pubitemid 38698205)
156. 4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 174, 5224-5232 (2005) (Pubitemid 40593160)
157. 4 receptor. Cytometry A 73, 299-304 (2008) (Pubitemid 351522112)
158. 4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther 307, 1072-1078 (2003) (Pubitemid 37494227)
159. 4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 309, 404-413 (2004) (Pubitemid 38393154)
160. 4 receptor. J Allergy Clin Immunol 120, 300-307 (2007) (Pubitemid 47102370)
161. 4 receptor. J Invest Dermatol 128, 1696-1703 (2008) (Pubitemid 351847377)
162. 4 histamine receptor in human natural killer cells, monocytes, and dendritic cells. J Immunol 179, 7907-7915 (2007)
163. 4 receptor in antiinflammatory therapy. Curr Top Med Chem 6, 1365-1373 (2006) (Pubitemid 44144922)
164. 4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 7, 41-53 (2008)
165. 4 receptor have a pro-or anti-inflammatory role in murine bronchial asthma? Pharmacology 85, 217-223 (2010)
166. 1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 142, 374-380 (2004) (Pubitemid 38750189)
167. 2 receptors control histamine-induced interleukin-16 release from human CD8 (+) T cells. J Pharmacol Exp Ther 303, 300-307 (2002)
168. 4 receptor agonist: (-)-2-cyano-1-methyl-3-((2R, 5R)-5-(1H-imidazol-4 (5) - yl) tetrahydrofuran-2-y) methylguanidine. J Med Chem 46, 3162-3165 (2003)
169. J. Selent, L. Lopez, F. Sanz, M. Pastor: Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new beta2 adrenergic receptor template. ChemMedChem 3, 1194-1198 (2008)
170. 4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. J Med Chem 49, 4512-4516 (2006) (Pubitemid 44162677)
171. 4 receptor ligands with anti-inflammatory properties in vivo. J Med Chem 51, 2457-2467 (2008) (Pubitemid 351628507)
172. 4 receptor agonist. J Med Chem 49, 6650-6651 (2006) (Pubitemid 44749731)
173. 4 receptor agonist VUF 8430. Br J Pharmacol 157, 34-43 (2009)
174. W. C. Lumma, Jr., R. D. Hartman, W. S. Saari, E. L. Engelhardt, V. J. Lotti, C. A. Stone: Piperazinylquinoxalines with central serotoninmimetic activity. J Med Chem 24, 93-101 (1981) (Pubitemid 11189908)
175. J. P. Edwards, J. D. Venable: Quinoxaline compounds. WO2005033088 (2005)
176. 4 receptor ligands. Drug Discov Today 14, 745-753 (2009)
177. 4 receptor. J Receptor Ligand Channel Res 3, 37-49 (2010)
178. 4 receptor antagonists. J Med Chem 46, 3957-3960 (2003) (Pubitemid 37122442)
179. 4 Antagonists. J Med Chem 48, 8289-8298 (2005) (Pubitemid 43032536)
180. 4 receptor antagonists. Bioorg Med Chem Lett 14, 5251-5256 (2004) (Pubitemid 39348908)
181. C. A. L. Lane, D. A. Price, S. Drouin: Octahydropyrrolo[3, 4-c]pyrrole derivatives. WO 2006056848 A1 (2006)
182. 4 receptor ligands. Bioorg Med Chem Lett 16, 6043-6048 (2006) (Pubitemid 44667812)
183. K. L. Arienti, J. G. Breitenbucher, D. J. Buzard, J. P. Edwards, M. D. Hack, H. Khatuya, D. E. Kindrachuk, A. Lee, J. D. Venable: Benzoimidazole compounds. WO2005044807 (2005)
184. 4 receptor. WO2007117399 (2007)
185. 4 receptor. WO2007117400 (2007)
186. 4 receptor ligands. Bioorg Med Chem Lett 20, 3367-3371 (2010)
187. D. J. Buzard, J. P. Edwards, D. E. Kindrachuk, J. D. Venable: Imidazole compounds. WO2005092066 (2005)
188. 4 Receptor Antagonists with an Imidazolylcyclopropane Structure. J Med Chem 49, 5587-5596 (2006) (Pubitemid 44373189)
189. 4 receptor inverse agonists using a scaffold hopping approach. J Med Chem 51, 7855-7865 (2008)
190. 4 receptor inverse agonists. J Med Chem 53, 2390-2400 (2010)
191. H. Sato, K. Tanaka, M. Shimazaki, K. Urbahns, K. Sakai, F. Gantner, K. Bacon: 2-Aminopyrimidine derivatives. WO2005054239 (2005)
192. H. Sato, K. Fukushima, M. Shimazaki, K. Urbahns, K. Sakai, F. Ganter, K. Bacon: 2-Aminopyrimidine derivatives. WO2005014556 (2005)
193. 4 receptor. WO2008100565 (2008)
194. A. S. Bell, C. A. L. Lane, C. E. Mowray, M. D. Selby, N. A. Swain, D. H. Williams: Pyrimidine derivatives. WO2007072163 (2007)
195. 4 receptor activity. WO2007031529 (2007)
196. G. Raphy, R. Watson, D. Hannah, C. Pergurier, I. Ortmans, C. J. Lock, R. L. Knight, D. A. Owen: Novel 2-amino-pyrimidine derivatives, processes for preparing them, pharmaceutical compositions thereof. WO2008031556 (2008)
197. 4 receptor ligands. J Med Chem 51, 6571-6580 (2008)
198. R. J. Altenbach, H. Liu, I. Drizin, N. Wishart, D. J. Babinski, R. J. Gregg, T. A. Esbenshade, G. C. Hsieh, J. D. Brioni, M. P. Honore, L. A. Black, C. Zhao, B. D. Wakefielf, A. A. Hancock, M. D. Cowart: A method for pain treatment. WO2008060766 (2008)
199. 4 receptor ligands - scaffold optimization and pharmacological characterization. Bioorg Med Chem 17, 7186-7196 (2009)
200. 4 receptor ligands. Inflamm Res 59, S249-S251 (2010)
201. 4 Receptor and their Impact on Receptor Activation. Chem Bio Chem 11, 1850-1855 (2010)
202. N. Harris, C. Higgs, S. Wren, H. J. Dyke, S. Price, S. Cramp: Pyrimidine compounds as histamine modulators. WO2006050965 (2006)
203. 4 receptor inverse agonists. Bioorg Med Chem Lett 20, 2516-2519 (2010)
204. A. Reid, F. Wilson, H. J. Dyke, S. Price, S. Cramp: Amino pyrimidine compounds for the treatment of inflammatory disorders. WO2007090852 (2007)
205. H. Dyke, S. Price, S. Cramp: Pyrimidine compounds for the treatment of inflammatory disorders. WO2007039467 (2007)
206. A. Reid, F. Wilson, H. J. Dyke, S. Price, S. Cramp: Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders. WO2007090853 (2007)
207. A. Reid, F. Wilson, H. J. Dyke, S. Price, S. Cramp: Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders. WO2007090854 (2007)
208. 4 receptor. WO2008008359 (2008)
209. R. J. Watson, D. Hannah, C. Pegurier, J. W. G. Meissner, D. Owen, F. Galvin: Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof. WO2008074445 (2008)
210. 4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J Med Chem 51, 6547-6557 (2008)
211. 4 receptor antagonists: effects of substitution about the rigidifying ring. Bioorg Med Chem Lett 20, 1900-1904 (2010)
212. R. J. Altenbach, H. Liu, I. Drizin, M. D. Cowart, N. Wishart, D. J. Babinski, R. J. Gregg, T. A. Esbenshade, G. C. Hsieh, J. D. Brioni, M. P. Honore, L. A. Black, C. Zhao, B. D. Wakefield, A. A. Hancock: Macrocyclic benzofused pyrimidine derivatives. WO2008060767 (2008)
213. 4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem 51, 7094-7098 (2008)
214. 4 receptor ligands by large-scale structurebased virtual screening. J Med Chem 51, 3145-3153 (2008) (Pubitemid 351821875)
215. S. Costanzi, I. G. Tikhonova, T. K. Harden, K. A. Jacobson: Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. J Comput Aided Mol Des 23, 747-754 (2009)
216. Y. Tanrikulu, G. Schneider: Pseudoreceptor models in drug design: bridging ligand-and receptor-based virtual screening. Nat Rev Drug Discov 7, 667-677 (2008)
217. T. Klabunde, G. Hessler: Drug design strategies for targeting G-protein-coupled receptors. Chem Bio Chem 3, 928-944 (2002) (Pubitemid 35189597)
218. A. Tropsha, S. X. Wang: QSAR modeling of GPCR ligands: methodologies and examples of applications. Ernst Schering Found Symp Proc 2, 49-73 (2006)
219. M. Congreve, F. Marshall: The impact of GPCR structures on pharmacology and structure-based drug design. Br J Pharmacol 159, 986-996 (2010)
220. B. K. Kobilka, X. Deupi: Conformational complexity of G protein-coupled receptors. Trends Pharmacol Sci 28, 397-406 (2007)
221. R. Vogel, M. Mahalingam, S. Lüdeke, T. Huber, F. Siebert, T. P. Sakmar: Functional role of the "ionic lock" - an interhelical hydrogen-bond network in family A heptahelical receptors. J Mol Biol 380, 648-655 (2008)
222. 4 receptor. J Pharmacol Exp Ther 333, 382-392 (2010)
223. S. G. Rasmussen, H. J. Choi, D. M. Rosenbaum, T. S. Kobilka, F. S. Thian, P. C. Edwards, M. Burghammer, V. R. Ratnala, R. Sanishvili, R. F. Fischetti, G. F. Schertler, W. I. Weis, B. K. Kobilka: Crystal structure of the human beta2 adrenergic Gproteincoupled receptor. Nature 450, 383-387 (2007) (Pubitemid 350126755)
224. 3 receptor antagonists derived from ligand based design. Bioorg Med Chem Lett 17, 3670-3675 (2007) (Pubitemid 46898822)
225. 3 antagonists. Bioorg Med Chem 13, 5647-5657 (2005) (Pubitemid 41187928)
226. 3 receptor antagonists, using the newly developed molecular modeling program SLATE. J Med Chem 44, 1666-1674 (2001) (Pubitemid 32852174)
227. S. Celanire, F. Lebon, H. Stark: Drug discovery: from hits to clinical candidates. In: The third histamine receptor: selective ligands as potential therapeutic agents in CNS disorders. Ed: D. S. Vohora. Taylor & Francis CRC Press Inc., Boca Raton (2008)
228. 2-receptor agonists. J Mol Graph 12, 242-256 (1994)
229. 4 receptor. Mol Pharmacol 62, 38-47 (2002) (Pubitemid 34680514)
230. 4 receptor. Eur J Med Chem 43, 1059-1070 (2008) (Pubitemid 351615244)
231. 4 receptor using mutational analysis, homology modeling, and ab initio calculations. J Chem Inf Model 48, 1455-1463 (2008)
232. 4 receptor - an explicit membrane molecular dynamics simulation study. J Chem Inf Model 48, 1199-1210 (2008)
233. 4R species variants. Mol Pharmacol 77, 734-743 (2010)
234. R. A. Clark, J. A. Sandler, J. I. Gallin, A. P. Kaplan: Histamine modulation of eosinophil migration. J Immunol 118, 137-145 (1977) (Pubitemid 8028913)
235. S. J. Hill, P. Chazot, H. Fukui, C. R. Ganellin, H. L. Haas, R. Hills, R. Levi, W. Schunack, J.-C. Schwartz, N. P. Shankley, H. Timmerman, J. M. Young: Histamine receptors. IUPHAR-DB
236. L. B. Hough: Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59, 415-419 (2001) (Pubitemid 32179917)
237. 4 receptor: drug discovery in the post-genomic era. In: Immunogenetics and Human Disease. Ed: A. Falus. John Wiley & Sons, (2006)
238. H. Stark: Histamine receptors. Biotrend Rev 1, 1-7 (2007)
239. 1 antihistamines: clinical relevance. Am J Med 113 Suppl 9A, 38S-46S (2002) (Pubitemid 36459495)
240. 1 receptor antagonists. Allergy 55 Suppl 64, 17-27 (2000)
241. 2 receptor antagonists: an overview. J Int Med Res 17 Suppl. 1, 9A-16A (1989)
242. 4 receptor ligands as potential modulators of inflammatory and allergic responses. Antiinflamm Antiallergy Agents Med Chem 5, 307-322 (2006) (Pubitemid 44734250)
243. L. Bielory, S. Ghafoor: Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 5, 437-440 (2005) (Pubitemid 41345313)
244. 4 receptor. Mol Pharmacol 76, 1019-1030 (2009)
245. 3 antagonist, 4 (5) - (5-aminopentyl)-1H-imidazole. J Med Chem 38, 266-271 (1995)
246. 3 receptor agonist. J Med Chem 47, 2414-2417 (2004) (Pubitemid 38580078)
247. 3 receptor agonist. J Med Chem 48, 2100-2107 (2005) (Pubitemid 40396337)
248. 3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J Pharmacol Exp Ther 305, 887-896 (2003) (Pubitemid 36617965)
249. 3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther 313, 165-175 (2005) (Pubitemid 40411340)
250. 4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol 147, 744-754 (2006)
251. 4 receptor antagonist with anti-inflammatory properties. Br J Pharmacol 157, 44-54 (2009)